

ONCOLYTICS BIOTECH INC

Form 6-K

July 10, 2006

**Table of Contents**

---

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

For the month of July, 2006

Commission File Number 000-31062

**Oncolytics Biotech Inc.**

---

*(Translation of registrant's name into English)*

**Suite 210, 1167 Kensington Crescent NW  
Calgary, Alberta, Canada T2N 1X7**

---

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 - \_\_\_\_\_

---

---

---

**TABLE OF CONTENTS**

Signatures

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Oncolytics Biotech Inc.**  
(Registrant)

Date: July 10, 2006

By: /s/ Doug Ball

\_\_\_\_\_  
Doug Ball  
Chief Financial Officer

**Table of Contents**

210, 1167 Kensington Crescent  
NW  
Calgary, Alberta  
Canada T2N 1X7

---

**For Immediate Release:**

**Oncolytics Biotech Inc. Commences Patient Enrolment in Phase Ib U.K. Clinical Trial Investigating REOLYSIN<sup>®</sup> in Combination with Radiation Therapy**

**CALGARY, AB, July 10, 2006** Oncolytics Biotech Inc. ( Oncolytics ) (TSX:ONC, NASDAQ:ONCY) announced today that it has commenced patient enrolment in its Phase Ib U.K. clinical trial investigating REOLYSIN<sup>®</sup> in combination with radiation therapy as a treatment for patients with advanced cancers. The Phase Ib trial will treat patients with a range of two to six intratumoural doses of REOLYSIN<sup>®</sup> at  $1 \times 10^{10}$  TCID<sub>50</sub> with a constant radiation dose of 36 Gy in 12 fractions.

Patient enrolment in the Ia combination REOLYSIN<sup>®</sup>/radiation trial was completed in June 2006. The Phase Ia trial tested two intratumoural treatments of REOLYSIN<sup>®</sup> at dosages of  $1 \times 10^8$ ,  $1 \times 10^9$ , or  $1 \times 10^{10}$  TCID<sub>50</sub> with a constant localized radiation dose of 20 Gy given in five fractions. A maximum tolerated dose (MTD) was not reached and the combination treatment appears to have been well tolerated by the patients. Interim results of the Ia trial were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C. in April 2006.

Preliminary analysis has demonstrated evidence of both local and systemic response.

The primary objective of the Phase Ib trial is to determine the MTD, dose limiting toxicity (DLT), and safety profile of REOLYSIN<sup>®</sup> when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. An additional group of patients is planned to be treated at the maximum dose regimen reached in the Ib trial.

The principal investigators for the trial are Dr. Kevin Harrington of the Targeted Therapy Laboratory, The Institute of Cancer Research, Cancer Research UK Centre for Cell and Molecular Biology and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust, London, UK, and Dr. Alan Melcher of the Cancer Research U.K. Clinical Centre at St. James' s University Hospital in Leeds. The trial is enrolling patients at the Royal Marsden and St. James' s Hospitals in the U.K.

**About Oncolytics Biotech Inc.**

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN<sup>®</sup>, its proprietary formulation of the human reovirus, alone and in combination with radiation. For further information about Oncolytics, please visit [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com)

*This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase Ia or Ib combination REOLYSIN<sup>®</sup>/radiation clinical trials, and the Company's belief as to the potential of REOLYSIN<sup>®</sup> as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN<sup>®</sup> as a cancer treatment, the tolerability of REOLYSIN<sup>®</sup> outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN<sup>®</sup>, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.*

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Oncolytics Biotech Inc.  
Cathy Ward  
210, 1167 Kensington Cr NW  
Calgary, Alberta T2N 1X7  
Tel: 403.670.7377  
Fax: 403.283.0858  
[cathy.ward@oncolytics.ca](mailto:cathy.ward@oncolytics.ca)  
[www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com)

The Equicom Group  
Nick Hurst  
20 Toronto Street  
Toronto, Ontario M5C 2B8  
Tel: 416.815.0700 ext. 226  
Fax: 416.815.0080  
[nhurst@equicomgroup.com](mailto:nhurst@equicomgroup.com)

The Investor Relations Group  
Damian McIntosh  
11 Stone Street, 3rd Floor  
New York, NY 10004  
Tel: 212.825.3210  
Fax: 212.825.3229  
[dmcintosh@investorrelationsgroup.com](mailto:dmcintosh@investorrelationsgroup.com)